2023
Neuroblastoma: an ongoing cold front for cancer immunotherapy. (Journal article)
Kennedy, P. T., Zannoupa, D., Son, M. H., Dahal, L. N., & Woolley, J. F. (2023). Neuroblastoma: an ongoing cold front for cancer immunotherapy.. Journal for immunotherapy of cancer, 11(11), e007798. doi:10.1136/jitc-2023-007798DOI: 10.1136/jitc-2023-007798
Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers (Other)
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Data from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.c.6513438.v1DOI: 10.1158/0008-5472.c.6513438.v1
Supplementary Figure 1 from STINGing Viral Tumors: What We Know from Head and Neck Cancers (Other)
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Supplementary Figure 1 from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.22429704DOI: 10.1158/0008-5472.22429704
Supplementary Figure 1 from STINGing Viral Tumors: What We Know from Head and Neck Cancers (Other)
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2023). Supplementary Figure 1 from STINGing Viral Tumors: What We Know from Head and Neck Cancers. doi:10.1158/0008-5472.22429704.v1DOI: 10.1158/0008-5472.22429704.v1
2022
Simpson, A. P., Roghanian, A., Oldham, R. J., Chan, H. T. C., Penfold, C. A., Kim, H. J., . . . Cragg, M. S. (2022). FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms. CELL REPORTS, 40(3). doi:10.1016/j.celrep.2022.111099DOI: 10.1016/j.celrep.2022.111099
Griffin, J. M., Healy, F. M., Dahal, L. N., Floisand, Y., & Woolley, J. F. (2022). Worked to the bone: antibody-based conditioning as the future of transplant biology. JOURNAL OF HEMATOLOGY & ONCOLOGY, 15(1). doi:10.1186/s13045-022-01284-6DOI: 10.1186/s13045-022-01284-6
Hussain, K., Liu, R., Smith, R. C. G., Muller, K. T. J., Ghorbani, M., Macari, S., . . . Cragg, M. S. (2022). HIF activation enhances FcγRIIb expression on mononuclear phagocytes impeding tumor targeting antibody immunotherapy. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 41(1). doi:10.1186/s13046-022-02294-5DOI: 10.1186/s13046-022-02294-5
Khanolkar, R. C., Zhang, C., Al-Fatyan, F., Lawson, L., Depasquale, I., Meredith, F. M., . . . Ward, F. J. (2022). TGF beta 2 Induces the Soluble Isoform of CTLA-4-Implications for CTLA-4 Based Checkpoint Inhibitor Antibodies in Malignant Melanoma. FRONTIERS IN IMMUNOLOGY, 12. doi:10.3389/fimmu.2021.763877DOI: 10.3389/fimmu.2021.763877
2021
Healy, F. M., Dahal, L. N., Jones, J. R. E., Floisand, Y., & Woolley, J. F. (2021). Recent Progress in Interferon Therapy for Myeloid Malignancies. FRONTIERS IN ONCOLOGY, 11. doi:10.3389/fonc.2021.769628DOI: 10.3389/fonc.2021.769628
Bloehdorn, J., Braun, A., Taylor-Weiner, A., Jebaraj, B. M. C., Robrecht, S., Krzykalla, J., . . . Mertens, D. (2021). Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-25403-yDOI: 10.1038/s41467-021-25403-y
STINGing Viral Tumors: What We Know from Head and Neck Cancers (Journal article)
Saulters, E., Woolley, J. F., Varadarajan, S., Jones, T. M., & Dahal, L. N. (2021). STINGing Viral Tumors: What We Know from Head and Neck Cancers. CANCER RESEARCH, 81(15), 3945-3952. doi:10.1158/0008-5472.CAN-21-0785DOI: 10.1158/0008-5472.CAN-21-0785
Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia (Journal article)
Alsufyani, A., Alanazi, R., Woolley, J. F., & Dahal, L. N. (2021). Old Dog, New Trick: Type I IFN-Based Treatment for Acute Myeloid Leukemia. MOLECULAR CANCER RESEARCH, 19(5), 753-756. doi:10.1158/1541-7786.MCR-20-0871DOI: 10.1158/1541-7786.MCR-20-0871
Wells, G., Kennedy, P. T., & Dahal, L. N. (n.d.). Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review. Frontiers in Immunology, 12. doi:10.3389/fimmu.2021.651687DOI: 10.3389/fimmu.2021.651687
2020
The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus (Journal article)
Dahal, L. N., Barker, R. N., & Ward, F. J. (2020). The Soluble Isoform of CTLA-4 Correlates with Interferon-α Activity in Systemic Lupus Erythematosus. JOURNAL OF RHEUMATOLOGY, 47(2), 302-304. doi:10.3899/jrheum.190678DOI: 10.3899/jrheum.190678
2019
Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia (Chapter)
Carter, M. J., Dahal, L. N., Cleary, K. L. S., Marshall, M. J. E., French, R. R., Beers, S. A., & Cragg, M. S. (2019). Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia. In CHRONIC LYMPHOCYTIC LEUKEMIA (Vol. 1881, pp. 173-184). doi:10.1007/978-1-4939-8876-1_14DOI: 10.1007/978-1-4939-8876-1_14
Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues (Journal article)
Sorrelle, N., Ganguly, D., Dominguez, A. T. A., Zhang, Y., Huang, H., Dahal, L. N., . . . Brekken, R. A. (2019). Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues. JOURNAL OF IMMUNOLOGY, 202(1), 292-299. doi:10.4049/jimmunol.1800878DOI: 10.4049/jimmunol.1800878
2018
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function (Journal article)
Buchan, S. L., Dou, L., Remer, M., Booth, S. G., Dunn, S. N., Lai, C., . . . Beers, S. A. (2018). Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function. IMMUNITY, 49(5), 958-970.e7. doi:10.1016/j.immuni.2018.09.014DOI: 10.1016/j.immuni.2018.09.014
Hiding in Plain Sight: Soluble Immunomodulatory Receptors (Journal article)
Dahal, L. N., Schwarz, H., & Ward, F. J. (2018). Hiding in Plain Sight: Soluble Immunomodulatory Receptors. TRENDS IN IMMUNOLOGY, 39(10), 771-774. doi:10.1016/j.it.2018.08.004DOI: 10.1016/j.it.2018.08.004
On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies (Journal article)
Ward, F. J., Dahal, L. N., & Abu-Eid, R. (2018). On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. FRONTIERS IN IMMUNOLOGY, 9, 12 pages. doi:10.3389/fimmu.2018.02182DOI: 10.3389/fimmu.2018.02182
Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy (Journal article)
Dahal, L. N., Huang, C. -Y., Stopforth, R. J., Mead, A., Chan, K., Bowater, J. X., . . . Beers, S. A. (2018). Shaving Is an Epiphenomenon of Type I and II Anti-CD20-Mediated Phagocytosis, whereas Antigenic Modulation Limits Type I Monoclonal Antibody Efficacy. JOURNAL OF IMMUNOLOGY, 201(4), 1211-1221. doi:10.4049/jimmunol.1701122DOI: 10.4049/jimmunol.1701122
UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion (Journal article)
Dahal, L. N., Gadd, A., Edwards, A. D., Cragg, M. S., & Beers, S. A. (2018). UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion. SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 87(6). doi:10.1111/sji.12666DOI: 10.1111/sji.12666
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies (Journal article)
Yu, X., Chan, H. T. C., Orr, C. M., Dadas, O., Booth, S. G., Dahal, L. N., . . . White, A. L. (2018). Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies. CANCER CELL, 33(4), 664-675. doi:10.1016/j.ccell.2018.02.009DOI: 10.1016/j.ccell.2018.02.009
New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B) (Journal article)
Roghanian, A., Stopforth, R. J., Dahal, L. N., & Cragg, M. S. (2018). New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcRIIB (CD32B). JOURNAL OF LEUKOCYTE BIOLOGY, 103(6), 1077-1088. doi:10.1002/JLB.2MIR0917-354RDOI: 10.1002/JLB.2MIR0917-354R
2017
Turaj, A. H., Hussain, K., Cox, K. L., Rose-Zerilli, M. J. J., Testa, J., Dahal, L. N., . . . Lim, S. H. (2017). Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment. CANCER CELL, 32(6), 777-791. doi:10.1016/j.ccell.2017.11.001DOI: 10.1016/j.ccell.2017.11.001
The dichotomy of T helper 17 cells in cancer (Journal article)
Dahal, L. N. (2017). The dichotomy of T helper 17 cells in cancer. NATURE REVIEWS IMMUNOLOGY, 17(9), 592-593. doi:10.1038/nri.2017.93DOI: 10.1038/nri.2017.93
STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy (Journal article)
Dahal, L. N., Dou, L., Hussain, K., Liu, R., Earley, A., Cox, K. L., . . . Beers, S. A. (2017). STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. Cancer Research, 77(13), 3619-3631. doi:10.1158/0008-5472.CAN-16-2784DOI: 10.1158/0008-5472.CAN-16-2784
TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter (Journal article)
Turaj, A. H., Dahal, L. N., Beers, S. A., Cragg, M. S., & Lim, S. H. (2017). TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter. CANCER RESEARCH, 77(12), 3376-3378. doi:10.1158/0008-5472.CAN-17-0412DOI: 10.1158/0008-5472.CAN-17-0412
PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis (Journal article)
Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2017). PI3K delta inhibition elicits anti-leukemic effects through Bim-dependent apoptosis. Leukemia, 31, 1423-1433. doi:10.1038/leu.2016.333DOI: 10.1038/leu.2016.333
2016
PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis (Conference Paper)
Carter, M. J., Cox, K. L., Blakemore, S. J., Turaj, A. H., Oldham, R. J., Dahal, L. N., . . . Cragg, M. S. (2016). PI3Kδ Inhibition Elicits Anti-Leukemic Effects through Bim-Dependent Apoptosis. In BLOOD Vol. 128. doi:10.1182/blood.V128.22.3241.3241DOI: 10.1182/blood.V128.22.3241.3241
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus (Journal article)
Dahal, L. N., Basu, N., Youssef, H., Khanolkar, R. C., Barker, R. N., Erwig, L. P., & Ward, F. J. (2016). Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus. ARTHRITIS RESEARCH & THERAPY, 18. doi:10.1186/s13075-016-1075-1DOI: 10.1186/s13075-016-1075-1
Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer? (Journal article)
Reddy, V., Dahal, L. N., Cragg, M. S., & Leandro, M. (2016). Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?. DRUG DISCOVERY TODAY, 21(8), 1330-1338. doi:10.1016/j.drudis.2016.06.009DOI: 10.1016/j.drudis.2016.06.009
2015
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors (Journal article)
Tutt, A. L., James, S., Laversin, S. A., Tipton, T. R. W., Ashton-Key, M., French, R. R., . . . Cragg, M. S. (2015). Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors. JOURNAL OF IMMUNOLOGY, 195(11), 5503-5516. doi:10.4049/jimmunol.1402988DOI: 10.4049/jimmunol.1402988
FcγR requirements leading to successful immunotherapy (Journal article)
Dahal, L. N., Roghanian, A., Beers, S. A., & Cragg, M. S. (2015). FcγR requirements leading to successful immunotherapy. IMMUNOLOGICAL REVIEWS, 268(1), 104-122. doi:10.1111/imr.12342DOI: 10.1111/imr.12342
Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo (Journal article)
Roghanian, A., Teige, I., Martensson, L., Cox, K. L., Kovacek, M., Ljungars, A., . . . Cragg, M. S. (2015). Antagonistic Human FcϒRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo. CANCER CELL, 27(04), 473-488. doi:10.1016/j.ccell.2015.03.005DOI: 10.1016/j.ccell.2015.03.005
Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies (Journal article)
Tipton, T. R. W., Roghanian, A., Oldham, R. J., Carter, M. J., Cox, K. L., Mockridge, C. I., . . . Beers, S. A. (2015). Antigenic modulation limits the effector cell mechanisms employed by type I anti-CD20 monoclonal antibodies. BLOOD, 125(12), 1901-1909. doi:10.1182/blood-2014-07-588376DOI: 10.1182/blood-2014-07-588376
Rehabilitation or the death penalty: Autoimmune B cells in the dock (Journal article)
Dahal, L. N., & Cragg, M. S. (2015). Rehabilitation or the death penalty: Autoimmune B cells in the dock. EUROPEAN JOURNAL OF IMMUNOLOGY, 45(3), 687-691. doi:10.1002/eji.201545464DOI: 10.1002/eji.201545464
2014
Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy? (Journal article)
Ward, F. J., Dahal, L. N., Khanolkar, R. C., Shankar, S. P., & Barker, R. N. (2014). Targeting the alternatively spliced soluble isoform of CTLA-4: prospects for immunotherapy?. IMMUNOTHERAPY, 6(10), 1073-1084. doi:10.2217/IMT.14.73DOI: 10.2217/IMT.14.73
Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads (Journal article)
Dahal, L. N., Barker, R. N., & Ward, F. J. (2014). Isolation, Polarization, and Expansion of CD4<SUP>+</SUP> Helper T Cell Lines and Clones Using Magnetic Beads. SYSTEMIC LUPUS ERYTHEMATOSUS: METHODS AND PROTOCOLS, 1134, 237-247. doi:10.1007/978-1-4939-0326-9_18DOI: 10.1007/978-1-4939-0326-9_18
Optimising macrophage phenotype and function for anti-tumour immunity (Conference Paper)
Dahal, L. N., Earley, A. J., Murinello, S., Teeling, J. L., Duriez, P. J., Houghton, F. D., . . . Cragg, M. S. (2014). Optimising macrophage phenotype and function for anti-tumour immunity. In IMMUNOLOGY Vol. 143 (pp. 125-126). Retrieved from https://www.webofscience.com/
2013
Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia. (Journal article)
Dahal, L. N., Hall, L. S., Barker, R. N., & Ward, F. J. (2013). Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia.. Clinical and experimental immunology, 173(1), 58-66. doi:10.1111/cei.12091DOI: 10.1111/cei.12091
The soluble isoform of CTLA-4 as a regulator of T-cell responses. (Journal article)
Ward, F. J., Dahal, L. N., Wijesekera, S. K., Abdul-Jawad, S. K., Kaewarpai, T., Xu, H., . . . Barker, R. N. (2013). The soluble isoform of CTLA-4 as a regulator of T-cell responses.. European journal of immunology, 43(5), 1274-1285. doi:10.1002/eji.201242529DOI: 10.1002/eji.201242529
